1. Alpha-mangostin improves endothelial dysfunction in db/db mice through inhibition of aSMase/ceramide pathway.
- Author
-
Jiang M, Huang S, Duan W, Liu Q, and Lei M
- Subjects
- Animals, Aorta metabolism, Cells, Cultured, Diabetic Angiopathies metabolism, Endothelial Cells drug effects, Endothelium, Vascular drug effects, Endothelium, Vascular metabolism, Insulin metabolism, Male, Mice, Mice, Inbred C57BL, Phosphorylation, Reactive Oxygen Species metabolism, Signal Transduction drug effects, Up-Regulation, Vasodilation drug effects, Xanthones pharmacology, Ceramides metabolism, Diabetes Mellitus, Experimental metabolism, Endothelial Cells metabolism, Nitric Oxide metabolism, Nitric Oxide Synthase Type III metabolism, Sphingomyelin Phosphodiesterase metabolism, Xanthones metabolism
- Abstract
Diabetic vascular complications are the leading causes of death and disability in patients with diabetes. Alpha-mangostin has been reported to have anti-diabetic capacity in recent years. Here, we investigated the protective function of alpha-mangostin on endothelium in vitro and in vivo experiments. We also observed that alpha-mangostin improved impaired endothelium-dependent vasodilation (EDV) of diabetic animals while it limited the aSMase/ceramide pathway and up-regulated eNOS/NO pathway in aortas from diabetic mice. Meanwhile, alpha-mangostin inhibited elevated aSMase/ceramide pathway and reversed impaired EDV induced by high glucose in isolated mouse aortas. In addition, alpha-mangostin increased phosphorylation of eNOS and NO production in high glucose-treated aortas. Alpha-mangostin normalized high glucose-induced activation of aSMase/ceramide pathway and improved eNOS/NO pathway in endothelial cells with high glucose. In conclusion, alpha-mangostin regulates eNOS/NO pathway and improves EDV in aortas of diabetic mice through inhibiting aSMase activity and endogenous ceramide accumulation., (© 2021 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd.)
- Published
- 2021
- Full Text
- View/download PDF